A Policy article in the May issue of The American Journal of Managed Care® suggests that sequential addition of SGLT2 inhibitors to DPP-4 inhibitors may be considered cost-effective compared with ...

Last year, an FDA advisory panel called for an updated label for saxagliptin, but the agency is still gathering information. An analysis of claims data found no association between the use of DPP-4 ...

LONDON--(BUSINESS WIRE)-- Pioglitazone use will continue to decrease, but most expect to increase their prescribing of DPP-IV inhibitors and GLP-1 agonists, according to a new report available on ...

Credit: Getty Images. To investigate the association between this diabetes drug class and IBD risk, the study authors searched various databases for controlled clinical trials and observational ...

Please provide your email address to receive an email when new articles are posted on . Insulin — not DPP-IV inhibitors or GLP-1 receptor agonists — should be the agent of choice for the management of ...

Adults with type 2 diabetes who are treated with DPP-IV inhibitors are more likely to develop pancreatitis and pancreatic cancer compared with those treated with other medications, according to ...

Higher risk of inflammatory bowel disease with longer use of dipeptidyl peptidase-4 inhibitor (HealthDay News) — Dipeptidyl peptidase-4 (DPP-4) inhibitors are associated with increased risk of ...

Across a broad swath of patients, short-term use of a sodium-glucose cotransporter 2 (SGLT2) inhibitor appears to reduce the risk of major adverse cardiovascular events, most notably cardiovascular ...

This first population-based study, found that DPP-4 inhibitors were associated with an increased risk of inflammatory bowel disease. (HealthDay News) — Dipeptidyl peptidase-4 (DPP-4) inhibitors are ...

Study results have validated that five routinely measured clinical values reliably identified patients with type 2 diabetes who had significantly different A1c responses to two important classes of ...

Among people with type 2 diabetes, new treatment with a dipeptidyl peptidase 4 (DPP-4) inhibitor was linked with higher risk of a rare blistering skin condition, researchers reported. Compared with ...

BURLINGTON, Mass. — Two classes of drugs for treating Type 2 diabetes will experience the biggest growth in market share of all classes of drugs for the condition, according to a new study by Decision ...